Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
548 hedge funds and large institutions have $26.9B invested in Alexion Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 191 increasing their positions, 193 reducing their positions, and 68 closing their positions.
57% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 68
50% more funds holding in top 10
Funds holding in top 10: 16 → 24 (+8)
6% more funds holding
Funds holding: 517 → 548 (+31)
2% more capital invested
Capital invested by funds: $26.3B → $26.9B (+$630M)
1% less repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 193
4% less call options, than puts
Call options by funds: $394M | Put options by funds: $412M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$408M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$261M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$211M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$166M |
| 5 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$149M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$981M |
| 2 |
JP Morgan Chase
New York
|
-$480M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$189M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$125M |
| 5 |
Goldman Sachs
New York
|
-$115M |
ALXN Hedge Fund Activity: Q4 2016 in Review
548 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2016, worth a combined $26.9B — up 2.4% from $26.3B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new ALXN positions and 68 closed out — a net gain of 39 holders — while 191 added to existing stakes and 193 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $408M. The largest seller was Capital Research Global Investors, cutting an estimated $981M.
- 548 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2016, up from 517 in Q3 2016.
- Funds reported $26.9B of Alexion Pharmaceuticals stock for Q4 2016, up 2.4% quarter-over-quarter.
- 107 funds opened new Alexion Pharmaceuticals positions in Q4 2016 and 68 closed out, a net change of +39 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2016 was Fidelity Investments, an estimated $408M added.
- The largest Alexion Pharmaceuticals seller in Q4 2016 was Capital Research Global Investors, an estimated $981M sold.
Based on aggregated 13F filings for Q4 2016.